Unmet Needs in IPF- and ILD-Related Pulmonary Hypertension and Emerging Therapy for IPF

Key Takeaways

• Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
• Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
• Personalized treatment approaches are needed to address individual patient variability in IPF and PAH.
• Enhanced understanding of pathophysiological mechanisms is crucial for novel therapeutic target development.